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Clinical PerspectiveWhat Is New?Given the low event rates in contemporary cohorts being worked up for chest pain, it is unclear whether noninvasive testing is associated with incremental downstream improvements in outcomes when compared with no testing.In our real‐world, population‐based cohort of adults discharged from the emergency department after evaluation for chest pain, noninvasive testing was associated with a small reduction in rates of downstream myocardial infarction or cardiovascular death.This reduced rate was driven by the high‐risk patient subgroup, and noninvasive testing did not confer benefit in intermediate‐ and low‐risk patient subgroups.What Are the Clinical Implications?Noninvasive testing after emergency department discharge may be overutilized in low‐ and intermediate‐risk patients.Risk‐based testing should be considered for patients discharged from the emergency department for chest pain.

Introduction {#jah34511-sec-0008}
============

Chest pain is one of the most common clinical manifestations of cardiovascular disease and results in the performance of more than 4 million cardiac noninvasive diagnostic tests annually in the United States, with accelerating utilization rates in recent years.[1](#jah34511-bib-0001){ref-type="ref"}, [2](#jah34511-bib-0002){ref-type="ref"}, [3](#jah34511-bib-0003){ref-type="ref"} However, despite widespread use, questions remain regarding the effectiveness of noninvasive tests in improving downstream clinical outcomes.[3](#jah34511-bib-0003){ref-type="ref"}, [4](#jah34511-bib-0004){ref-type="ref"}, [5](#jah34511-bib-0005){ref-type="ref"}, [6](#jah34511-bib-0006){ref-type="ref"}, [7](#jah34511-bib-0007){ref-type="ref"}, [8](#jah34511-bib-0008){ref-type="ref"} PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) and SCOT‐HEART (Scottish Computed Tomography of the HEART Trial) reported low rates of major adverse cardiovascular events (MACE) in patients undergoing different types of noninvasive tests.[2](#jah34511-bib-0002){ref-type="ref"}, [9](#jah34511-bib-0009){ref-type="ref"}, [10](#jah34511-bib-0010){ref-type="ref"} Given the low event rates in contemporary cohorts being worked up for chest pain, it is unclear whether noninvasive testing (NIT) can lead to incremental downstream improvements in outcomes when compared with no testing. Unfortunately, neither the PROMISE nor the SCOT‐HEART trial included no‐testing arms to compare outcomes between strategies of *any* NIT versus no testing in order to help shed light onto this question.

In order to further explore the utility of NIT in patients evaluated for chest pain we sought to evaluate whether any such testing is associated with lower rates of MACE when compared with no testing. In order to address this objective, we used a well‐defined cohort of patients who were recently discharged from the emergency department (ED) after assessment for chest pain in which a potential cardiac etiology was considered and an acute coronary syndrome was ruled out. We hypothesized that there would be no significant difference in outcomes between those patients who underwent NIT and those who were not tested.

Methods {#jah34511-sec-0009}
=======

Availability of Data {#jah34511-sec-0010}
--------------------

The data set from this study is held securely in coded form at ICES. While data‐sharing agreements prohibit ICES from making the data set publicly available, access may be granted to those who meet prespecified criteria for confidential access, available at [www.ices.on.ca/DAS](http://www.ices.on.ca/DAS). The full data set creation plan and underlying analytic code are available from the authors upon request, understanding that the programs may rely on coding templates or macros that are unique to ICES.

Design and Derivation of the Cohort {#jah34511-sec-0011}
-----------------------------------

We employed a retrospective cohort study design. Patients entered the cohort if they were evaluated for chest pain in an ED in Ontario, Canada, between April 1, 2010, and November 30, 2015, and discharged home after evaluation. Moreover, to be included in the cohort, patients must have undergone an ECG within 1 day of the ED visit. Patients were followed for 30 days after the index chest pain visit to determine whether they received 1 of 4 NITs currently available in Ontario: Graded exercise stress test, stress echocardiography, myocardial perfusion imaging, or coronary computed tomography angiography. Those undergoing testing were classified in the NIT arm of the study and those who did not were classified in the nontesting arm. We excluded patients who underwent an ED visit for chest pain or an NIT during the preceding 12 months. We also excluded patients older than 80 years. In elderly patients, comorbid conditions such as frailty are highly influential in physicians' decisions not to pursue testing. Thus, we believed that including this group of elderly patients in our cohort would introduce unacceptable bias into our study.

Data Sources {#jah34511-sec-0012}
------------

The National Ambulatory Care Reporting System (NACRS) was used to determine patient ED visits. NACRS contains data for all hospital‐ and community‐based ambulatory care in Canada including information on ED discharge diagnosis.[11](#jah34511-bib-0011){ref-type="ref"}, [12](#jah34511-bib-0012){ref-type="ref"} Information to identify patient receipt of NIT and ECGs was obtained from the Ontario Health Insurance Plan (OHIP) physician claims database using billing codes that were used in previous studies.[13](#jah34511-bib-0013){ref-type="ref"}, [14](#jah34511-bib-0014){ref-type="ref"} Cardiovascular death was determined from the Office of the Registrar General‐Deaths database (*International Classification of Diseases, Ninth Revision* \[*ICD‐9*\] codes I00--I78). This is a data set containing information on all registered deaths in Ontario including cause of death. Physician specialty was determined by linking the OHIP database with the ICES physician database. The RPDB (Registered Persons Database), a registry of Ontario residents who are registered for Ontario health insurance coverage, was used to obtain demographic information. Median neighborhood income was obtained by linking the Census Area Profile with patients' postal codes of residence from RPDB using the Postal Code Conversion File. Hospitalizations, including those for acute myocardial infarction (MI), were determined using the Canadian Institutes for Health Information (CIHI) Discharge Abstract Database (CIHI‐DAD). This database was also used to determine receipt of invasive angiography, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG). The Ontario Hypertension Database and Ontario Diabetes Databases were used to obtain hypertension and diabetes mellitus status, respectively. The Ontario Drug Benefit database was used to determine receipt of prescription medication in patients 65 years and older.

These data sets were linked using unique encoded identifiers and analyzed at ICES. The use of data in this project was authorized under section 45 of Ontario\'s Personal Health Information Protection Act, which does not require review by a research ethics board or informed consent of study participants. Given Canada\'s single‐payer government‐funded healthcare system, we were able to extract patient information with virtually 100% coverage of the population of Ontario.

Processes of Care {#jah34511-sec-0013}
-----------------

Patients were followed for a maximum of 1 year after presentation for chest pain in order to ascertain receipt of angiography, PCI, CABG, and physician follow‐up by both general practitioners and cardiologists.

Outcomes {#jah34511-sec-0014}
--------

The main outcome was a composite of time to hospitalization for acute MI or cardiovascular death. This outcome was ascertained for a maximum of 1 year after the date of NIT or the assigned pseudo‐test date. Since the last person entering our cohort could have entered it on November 30, 2015, the follow‐up period to evaluate for outcomes was extended to December 31, 2016. Definitions that we used to determine these outcomes have been previously validated using administrative data from CIHI‐DAD and have been extensively utilized in the literature.[15](#jah34511-bib-0015){ref-type="ref"}, [16](#jah34511-bib-0016){ref-type="ref"}, [17](#jah34511-bib-0017){ref-type="ref"}, [18](#jah34511-bib-0018){ref-type="ref"}, [19](#jah34511-bib-0019){ref-type="ref"}

Statistical Analysis {#jah34511-sec-0015}
--------------------

Propensity score matching was employed to account for potential imbalances in measured baseline covariates between the testing and no‐testing groups. The propensity score was estimated using a random effects logistic regression model that incorporated physician‐specific random effects that accounted for the clustering of patients within the most‐responsible ED physician. Using this model, we regressed receipt of testing within 30 days of the index ED visit (versus no testing within 30 days) on the following baseline covariates: age, Charlson comorbidity score, tertile of hospital ED volume, sex, rural location, income quintile, diabetes mellitus, dyslipidemia, hypertension, chronic obstructive pulmonary disease, active cancer, metastatic cancer, type of hospital (teaching versus community and hospitals capable of performing PCI versus those that are not), history of heart failure, unstable angina, MI, peripheral vascular disease, revascularization (PCI/CABG), cerebrovascular disease, and whether the patient was assessed by a cardiologist in the ED. The index date for those undergoing NIT was the date of testing. For patients not undergoing testing, pseudo‐test dates were then created in the following manner. We estimated the empirical distribution of lag times (time between ED discharge and testing) for patients who underwent testing within 30 days. For each nontest patient, a random lag time was drawn from the empirical distribution determined above. This lag time was then added to each nontest patient to derive their pseudo‐test date. Patients who experienced cardiovascular death before their test or pseudo‐test date were excluded. This method was employed to both minimize the potential for immortal time bias while maintaining the maximum number of outcome events in our analyses and has been previously utilized by our group when evaluating the impact of electrophysiology visits on outcomes in patients with atrial fibrillation.[20](#jah34511-bib-0020){ref-type="ref"} The propensity score was estimated using variables measured at the index date. Propensity score matching was used to match test and nontest patients. Participants were matched on the logit of the propensity score using calipers with a width of 0.2 of the SD of the logit of the propensity score.[21](#jah34511-bib-0021){ref-type="ref"} Standardized differences were used in the unmatched and matched samples to assess for balance of baseline covariates between the testing and nontesting groups. A standardized difference of \<0.10 was deemed to be acceptable. Patients were then followed from the test/pseudo‐test date to determine outcomes.

After matching was complete, processes of care and outcomes at 90 days and 1 year after the test/pseudo‐test date were determined and compared between the 2 groups. Given the presence of competing risks (eg, noncardiovascular death), a cause‐specific hazards model was used to compare the rate of our composite outcome of time to MI and/or cardiovascular death between the testing and no‐testing groups.[22](#jah34511-bib-0022){ref-type="ref"} A robust variance estimator was used to account for the matched nature of the sample.[21](#jah34511-bib-0021){ref-type="ref"} This model allows for a comparison of the cause‐specific hazard of cardiovascular death or MI between the 2 groups. It is equivalent to the Cox proportional hazards model in the setting without competing risks.

Subgroup Analyses {#jah34511-sec-0016}
-----------------

To ascertain whether cardiovascular risk influences the relationship between NIT and outcomes, we stratified our analyses according to the baseline cardiovascular risk of the patient. We did this by matching on the propensity score and subgroup variable. We defined patients as high risk if he/she had a prior MI, unstable angina, or a revascularization procedure (PCI or CABG). Patients with ≥1 cardiovascular risk factor (eg, dyslipidemia, diabetes mellitus, or hypertension) were categorized as intermediate risk. Patients with no cardiovascular risk factors were categorized as low risk. Comorbidities or cardiac procedures within 5 years of the index event were identified. The risk‐stratification tool that we used has been previously shown by our group to be able to classify patients discharged from the ED into different strata of adverse outcomes.[11](#jah34511-bib-0011){ref-type="ref"}, [23](#jah34511-bib-0023){ref-type="ref"}

Cumulative Incidence Frequency Curves {#jah34511-sec-0017}
-------------------------------------

Cumulative incidence frequency curves for the incidence of the main outcome were constructed for the testing and nontesting arms both for the overall cohort and for each risk strata. These curves accounted for the competing risk of noncardiovascular death. Cumulative incidence frequency curves were compared between groups using the Wald test from a Fine‐Gray model that accounted for clustering within matched pairs in a manner previously described.[24](#jah34511-bib-0024){ref-type="ref"}

Results {#jah34511-sec-0018}
=======

Derivation of the Study Cohort {#jah34511-sec-0019}
------------------------------

A total of 497 013 patients were discharged home after ED assessment for chest pain from hospitals across Ontario between April 1, 2010, and November 30, 2015. Of these, 125 957 patients were excluded for having a visit to the ED for chest pain or an NIT in the prior year or for not having an ECG performed within 1 day of the ED visit, and 193 patients were excluded before their pseudo‐test date. A total of 370 863 patients remained in our final cohort (Figure [1](#jah34511-fig-0001){ref-type="fig"}).

![Derivation of the study cohort. ED indicates emergency department; NIT, noninvasive testing.](JAH3-8-e013824-g001){#jah34511-fig-0001}

Baseline Characteristics {#jah34511-sec-0020}
------------------------

Baseline characteristics of patients before propensity score matching are summarized in Table [S1](#jah34511-sup-0001){ref-type="supplementary-material"}. Patient baseline characteristics after matching are summarized in Table [1](#jah34511-tbl-0001){ref-type="table"}. We were able to identify 96 457 propensity score--matched pairs. A total of 95% of patients with NIT were successfully matched. The testing and nontesting groups were well balanced, with no meaningful differences (presence of a standardized difference \>0.10) between the groups in terms of age, sex, other cardiovascular risk factors, income distribution, or noncardiac comorbidities. Further, there were no significant differences in the matched sample between the testing and the nontesting groups with regards to the types of hospitals in which the patients were assessed. Approximately 15% of patients were assessed in the EDs of teaching hospitals and 35% of patients were assessed in hospitals with cardiac catheterization capabilities.

###### 

Baseline Patient Characteristics After the Propensity Score Match

  Baseline Characteristic                                              No Testing (n=96 457)   Testing (n=96 457)   Standardized Difference
  -------------------------------------------------------------------- ----------------------- -------------------- -------------------------
  Age, mean±SD, y                                                      56.8±10.5               56.8±10.4            \<0.01
  Women                                                                47 594 (49.3)           48 296 (50.1)        0.01
  Income quintile                                                                                                   
  1                                                                    17 352 (18.0)           18 013 (18.7)        0.02
  2                                                                    18 658 (19.3)           18 841 (19.5)        \<0.01
  3                                                                    19 707 (20.4)           19 669 (20.4)        \<0.01
  4                                                                    20 752 (21.5)           20 442 (21.2)        0.01
  5                                                                    19 770 (20.5)           19 264 (20.0)        0.01
  Rural location of the test                                           10 128 (10.5)           10 683 (11.1)        0.02
  Median time to test or pseudo‐test (IQR), d                          9.0 (4.0--18.0)         9.0 (4.0--17.0)      0.04
  Assessment in a teaching hospital                                    14 082 (14.6)           14 854 (15.4)        0.02
  Assessment in a hospital with cardiac catheterization capabilities   34 425 (35.7)           33 846 (35.1)        0.01
  Evaluated by a cardiologist while in the ED                          1218 (1.3)              1233 (1.3)           \<0.01
  Risk group                                                                                                        
  High                                                                 6178 (6.4)              6178 (6.4)           \<0.01
  Intermediate                                                         62 065 (64.3)           62 065 (64.3)        \<0.01
  Low                                                                  28 214 (29.3)           28 214 (29.3)        \<0.01
  Hospital volume                                                                                                   
  High                                                                 26 044 (27.0)           27 045 (28.0)        0.02
  Intermediate                                                         33 714 (35.0)           33 818 (35.1)        \<0.01
  Low                                                                  36 699 (38.1)           35 594 (36.9)        0.02
  Comorbidities in the past 5 y                                                                                     
  Unstable angina                                                      1962 (2.0)              1975 (2.1)           \<0.01
  Congestive heart failure                                             633 (0.7)               600 (0.6)            \<0.01
  MI                                                                   2544 (2.6)              2512 (2.6)           0.01
  Peripheral vascular disease                                          2093 (2.2)              2087 (2.2)           \<0.01
  Cerebrovascular disease                                              656 (0.7)               678 (0.7)            \<0.01
  Cancer                                                               2457 (2.6)              2599 (2.7)           0.01
  Renal disease                                                        455 (0.5)               439 (0.5)            \<0.01
  Diabetes mellitus                                                    18 210 (18.9)           18 266 (18.9)        0.01
  Dyslipidemia                                                         48 745 (50.5)           48 676 (50.5)        \<0.01
  Hypertension                                                         43 741 (45.4)           44 103 (45.7)        0.01
  Chronic obstructive pulmonary disease                                814 (0.8)               902 (0.9)            0.01
  Charlson score, mean (SD)                                            0.3±0.8                 0.3±0.8              0.01
  Medication use in the previous 90 d (in patients 65 y and older)                                                  
  ACEIs/ARBs                                                           10 925 (45.5)           10 886 (45.5)        \<0.01
  Statins                                                              10 611 (44.2)           10 551 (44.1)        \<0.01
  β‐Blockers                                                           5979 (24.9)             5394 (22.6)          0.06

Values are expressed as number (percentage) unless otherwise indicated. ACEIs indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; ED, emergency department; IQR, interquartile range.

Risk stratification: high risk: prior myocardial infarction (MI), unstable angina, or a revascularization procedure (percutaneous coronary intervention or coronary artery bypass grafting); intermediate risk: ≥1 cardiovascular risk factor (eg, dyslipidemia, diabetes mellitus, or hypertension); low risk: no cardiovascular risk factors.

Processes of Care {#jah34511-sec-0021}
-----------------

Patients who underwent testing were 11% more likely to see a family physician within 1 year after discharge (hazard ratio \[HR\], 1.11; 95% CI, 1.10--1.12). They were also 74% more likely to consult with a cardiologist during the same time frame (HR, 1.74; 95% CI, 1.72--1.77).

At both 90 days and 1‐year postdischarge, patients who received NIT were more likely to undergo invasive evaluation and revascularization. At 1 year, they were almost 3‐fold more likely to undergo invasive angiography (HR, 2.83; 95% CI, 2.72--2.95), ≈2.5‐fold more likely to undergo PCI (HR, 2.54; 95% CI, 2.36--2.73), and ≈2.5‐fold more likely to undergo CABG (HR, 2.53; 95% CI, 2.25--2.85). Patients undergoing NIT and 65 years and older were more likely to be prescribed cardiac medications, namely angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers (≈10% more likely), statins (≈16% more likely), or β‐blockers (≈11% more likely), when compared with patients not undergoing testing (see Table [2](#jah34511-tbl-0002){ref-type="table"}).

###### 

Processes of Care at 90 d and 1 y, Comparing the No‐Testing and Testing Groups

                                 No Testing       Testing          HR (95% CI)
  ------------------------------ ---------------- ---------------- -------------------
  90 d                                                             
  Invasive angiography           1517 (1.57)      6593 (6.84)      4.48 (4.23--4.73)
  PCI                            479 (0.50)       1889 (1.96)      3.97 (3.59--4.39)
  CABG                           187 (0.19)       633 (0.66)       3.39 (2.88--3.99)
  Cardiologist visit             13 975 (14.49)   26 530 (27.50)   2.08 (2.03--2.12)
  Primary care physician visit   65 861 (68.28)   70 163 (72.74)   1.14 (1.13--1.16)
  ACEIs/ARBs                     11 225 (46.78)   11 982 (50.10)   1.11 (1.08--1.14)
  Statins                        11 052 (46.05)   12 306 (51.46)   1.17 (1.14--1.20)
  β‐Blockers                     6458 (26.91)     7168 (29.97)     1.15 (1.12--1.19)
  1 y                                                              
  Invasive angiography           3107 (3.22)      8475 (8.79)      2.83 (2.72--2.95)
  PCI                            970 (1.01)       2442 (2.53)      2.54 (2.36--2.73)
  CABG                           376 (0.39)       950 (0.96)       2.53 (2.25--2.85)
  Cardiologist visit             21 794 (22.60)   33 967 (35.22)   1.74 (1.72--1.77)
  Primary care physician visit   87 593 (90.81)   88 950 (92.22)   1.11 (1.10--1.12)
  ACEIs/ARBs                     13 061 (54.43)   13 784 (57.64)   1.10 (1.07--1.12)
  Statins                        13 372 (55.72)   14 626 (61.16)   1.16 (1.14--1.19)
  β‐Blockers                     7791 (32.47)     8345 (34.89)     1.11 (1.08--1.15)

Values are expressed as number (percentage) unless otherwise indicated. ACEIs indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.

Medication use is reported in patients 65 years and older.

Outcomes {#jah34511-sec-0022}
--------

Event rates were low for both groups, with only ≈0.3% of patients in either group having an MI or experiencing cardiovascular death within 90 days of the ED visit (Table [3](#jah34511-tbl-0003){ref-type="table"}). These trends persisted for the duration of our follow‐up, with only 0.68% of patients in the testing and 0.78% of patients in the nontesting group experiencing the composite outcome within 1 year after presentation to the ED (Table [4](#jah34511-tbl-0004){ref-type="table"}). Patients undergoing testing did not have significantly different hazards of experiencing the composite outcome over 90 days after the test date/pseudo‐test date when compared with those who were not tested (HR, 1.17; 95% CI, 1.00--1.37 \[*P*=0.05\]) (Figure [2](#jah34511-fig-0002){ref-type="fig"}A). However, over 1 year, patients who underwent testing had a small but statistically significant lower hazard of developing the composite outcome when compared with those who were not tested (HR, 0.87; 95% CI, 0.78--0.96 \[*P*\<0.01\]) (Figure [2](#jah34511-fig-0002){ref-type="fig"}B). The number needed to treat to prevent 1 event of MI or cardiovascular death was 974 at this 1‐year time frame.

###### 

Outcomes at 90 d, Comparing the No‐Testing and Testing Groups

                             No Testing   Testing                                       Adjusted HR (95% CI)   *P* Value
  -------------------------- ------------ --------------------------------------------- ---------------------- -----------
  Overall                                                                                                      
  Cardiovascular death, MI   281 (0.29)   329 (0.34)                                    1.17 (1.00--1.37)      0.05
  Cardiovascular death       87 (0.09)    37 (0.04)                                     0.43 (0.29--0.63)      \<0.01
  MI                         205 (0.21)   296 (0.31)                                    1.45 (1.21--1.73)      \<0.01
  High risk                                                                                                    
  Cardiovascular death, MI   73 (1.18)    69 (1.12)                                     0.95 (0.68--1.31)      0.74
  Cardiovascular death       30 (0.49)    13 (0.21)                                     0.43 (0.23--0.83)      \<0.01
  MI                         45 (0.73)    57 (0.92)                                     1.27 (0.86--1.88)      0.23
  Intermediate risk                                                                                            
  Cardiovascular death, MI   172 (0.28)   203 (0.33)                                    1.18 (0.96--1.45)      0.11
  Cardiovascular death       48 (0.08)    19 (0.03)                                     0.40 (0.23--0.67)      \<0.01
  MI                         132 (0.21)   187 (0.30)                                    1.42 (1.13--1.77)      \<0.01
  Low risk                                                                                                     
  Cardiovascular death, MI   36 (0.13)    57 (0.20)                                     1.58 (1.04--2.41)      0.03
  Cardiovascular death       9 (0.03)     ≤5[\*](#jah34511-note-0007){ref-type="fn"}    0.56 (0.19--1.66)      0.29
  MI                         28 (0.10)    ≥50[\*](#jah34511-note-0007){ref-type="fn"}   1.86 (1.17--2.94)      \<0.01

Values are expressed as number (percentage) unless otherwise indicated. HR indicates hazard ratio.

Due to reidentification risk, ICES prohibits publication of cell sizes of \<6.

Risk stratification: high risk: prior myocardial infarction (MI), unstable angina, or a revascularization procedure (percutaneous coronary intervention or coronary artery bypass grafting); intermediate risk: ≥1 cardiovascular risk factors (eg, dyslipidemia, diabetes mellitus, or hypertension); low risk: no cardiovascular risk factors.

###### 

Outcomes at 1 y, Comparing the No‐Testing and Testing Groups

                             No Testing   Testing      Adjusted HR (95% CI)   *P* Value
  -------------------------- ------------ ------------ ---------------------- -----------
  Overall                                                                     
  Cardiovascular death, MI   754 (0.78)   655 (0.68)   0.87 (0.78--0.96)      \<0.01
  Cardiovascular death       241 (0.25)   124 (0.13)   0.51 (0.41--0.64)      \<0.01
  MI                         544 (0.56)   548 (0.57)   1.00 (0.90--1.13)      0.90
  High risk                                                                   
  Cardiovascular death, MI   222 (3.59)   167 (2.70)   0.75 (0.61--0.92)      \<0.01
  Cardiovascular death       88 (1.42)    43 (0.70)    0.49 (0.39--0.70)      \<0.01
  MI                         142 (2.30)   133 (2.15)   0.94 (0.74--1.19)      0.58
  Intermediate risk                                                           
  Cardiovascular death, MI   436 (0.70)   385 (0.62)   0.88 (0.77--1.01)      0.07
  Cardiovascular death       125 (0.20)   63 (0.10)    0.50 (0.37--0.68)      \<0.01
  MI                         330 (0.53)   328 (0.53)   0.99 (0.85--1.16)      0.94
  Low risk                                                                    
  Cardiovascular death, MI   96 (0.34)    103 (0.37)   1.07 (0.81--1.42)      0.62
  Cardiovascular death       28 (0.10)    18 (0.06)    0.64 (0.36--1.16)      0.14
  MI                         72 (0.26)    87 (0.31)    1.21 (0.88--1.65)      0.23

Values are expressed as number (percentage) unless otherwise indicated. HR indicates hazard ratio.

Risk stratification: high risk: prior myocardial infarction (MI), unstable angina, or a revascularization procedure (percutaneous coronary intervention or coronary artery bypass grafting); intermediate risk: ≥1 cardiovascular risk factors (eg, dyslipidemia, diabetes mellitus, or hypertension); low risk: no cardiovascular risk factors.

![**A**, Cardiovascular death or myocardial infarction (MI) at 90 days: testing vs nontesting groups. **B**, Cardiovascular death or MI at 1 year: testing vs nontesting groups.](JAH3-8-e013824-g002){#jah34511-fig-0002}

Subgroup Analyses According to Cardiovascular Risk {#jah34511-sec-0023}
--------------------------------------------------

A total of 30 983 patients in our cohort were categorized as high risk, while 221 096 were categorized as intermediate risk and 118 784 as low risk. High‐risk patients in our cohort who underwent testing had significantly lower hazards of MI or death when compared with similar‐risk patients who were not tested. At 1 year, they experienced an ≈25% reduction in cardiovascular death and MI when compared with high‐risk patients who were not tested (HR, 0.75; 95% CI, 0.61--0.92 \[*P*\<0.01\]) (Table [4](#jah34511-tbl-0004){ref-type="table"}). The number needed to treat to prevent 1 event of MI or cardiovascular death was 112 in the high‐risk subgroup. In contrast, for the intermediate‐ and low‐risk groups, there were no significant reductions in the composite outcome attributed to testing. Cumulative incidence frequency curves highlight the discrepancy between the high‐ and the intermediate‐ and low‐risk groups with respect to the impact of NIT (Figure [3](#jah34511-fig-0003){ref-type="fig"}).

![Cumulative incidence frequency curves for the low‐, intermediate‐, and high‐risk groups comparing cardiovascular (CV) death or myocardial infarction (MI) between the testing and the nontesting groups.](JAH3-8-e013824-g003){#jah34511-fig-0003}

Discussion {#jah34511-sec-0024}
==========

In our large, population‐based study we report that there were low rates of MI and cardiovascular death in patients discharged from the ED after assessment for chest pain. Further, those tested were more likely to pursue follow‐up with both family physicians and cardiologists and undergo invasive angiography and revascularization procedures. At 1 year, patients who were tested experienced a significant reduction in the hazards for cardiovascular death or acute MI. This result was driven by the high‐risk subgroup. There were no significant improvements in outcomes in either the low‐ or intermediate‐risk patient groups that were attributable to NIT.

It is currently unclear whether more NIT leads to better outcomes in patients undergoing evaluation for CAD. The question of whether *any* NIT results in improved clinical outcomes was reinforced when 2 large trials, the PROMISE and SCOT‐HEART trials, as well as large observational population‐based studies, reported low rates of MI and death.[2](#jah34511-bib-0002){ref-type="ref"}, [9](#jah34511-bib-0009){ref-type="ref"}, [10](#jah34511-bib-0010){ref-type="ref"}, [25](#jah34511-bib-0025){ref-type="ref"} Importantly, neither the PROMISE nor the SCOT‐HEART trial had "no‐testing" arms. In this study, we gained insights into the utility of NIT for coronary artery disease by evaluating the subset of patients who presented to the ED with chest pain and who were subsequently discharged home.

Currently, the American Heart Association strongly advocates for performing NIT in patients who present for chest pain to the ED in whom an ACS has been excluded.[26](#jah34511-bib-0026){ref-type="ref"} This recommendation is largely based on older data reporting relatively high rates of MI and death in patients discharged from the ED after presentation with chest pain.[27](#jah34511-bib-0027){ref-type="ref"} However, in contemporary practice, there is little evidence to support the fact that NIT in this setting leads to improvements in clinical outcomes. One recent study using administrative data of privately insured individuals in the United States reported low 1‐year rates of MI in patients discharged from the ED after being assessed for chest pain.[28](#jah34511-bib-0028){ref-type="ref"} Similar to this study, our population‐based data reported low rates of MI and cardiovascular death in patients discharged from the ED after presentation with chest pain. In addition, our results demonstrated a small overall reduction in MACE, driven by reductions in cardiovascular mortality, for patients undergoing NIT. This reduction in MACE was driven by the high‐risk patient group.

It is important to note that we observed higher rates of processes of care in the NIT arm of our study. For example, we found that patients undergoing NIT also underwent more downstream revascularization procedures and were more likely to be started on medications such as statins. They were also more likely to undergo evaluation by a cardiologist. We speculate that NIT may have initiated a cascade of events leading to improved downstream processes of care that ultimately may have led to the lower rates of MACE that we observed. While this cascade of events is speculative, it is consistent with the overall rationale of evaluating outcomes related to diagnostic testing strategies. This rationale argues that evaluation of outcomes in this context is not simply a reflection of receipt or nonreceipt of the diagnostic test itself but rather is also indicative of a chain of real‐world events and decisions triggered by the diagnostic test that ultimately lead to potential observed differences in cardiovascular outcomes.[2](#jah34511-bib-0002){ref-type="ref"}, [29](#jah34511-bib-0029){ref-type="ref"}

Clinical Importance and Health Policy Implications {#jah34511-sec-0025}
--------------------------------------------------

To the best of our knowledge, our study is the first to compare mortality between testing and no‐testing strategies in patients being evaluated for CAD following ED discharge after presentation for chest pain. Our results argue against the guideline recommendations for broad‐based testing and suggest that a risk‐based decision to defer testing or a "watchful waiting" strategy of careful management of cardiovascular risk factors in low‐ and intermediate‐risk patients may be appropriate and sufficient in many situations. Limiting diagnostic testing to patients most likely to benefit is important given its proliferation over the past few decades, its associated costs, and the resultant emphasis that researchers and policy makers are currently placing on the importance of choosing diagnostic testing wisely.

Study Limitations {#jah34511-sec-0026}
-----------------

This study must be interpreted in the context of its limitations. First, as this is an observational study, there is the potential for selection bias in terms of who did and did not get tested. To mitigate against this limitation, we used a well‐defined patient population and propensity score matching to account for observed differences between patients tested and patients who were not--ensuring balance in terms of clinically important covariates. While this technique accounted for measured covariates, it is incapable of addressing the potential impact of unmeasured covariates, such as chest pain characteristics and ECG findings, which are often important in the physician decision‐making process when ordering noninvasive testing. Second, these results reflect patterns of care and outcomes in Ontario and may not necessarily be generalizable to other jurisdictions. However, Ontario is a large and diverse province consisting of ≈14 million people, similar in nature to many diverse populations around the world. The population‐level analyses that we performed (ie, having virtually 100% coverage of the population) further enhances the generalizability of our findings. Third, we did not use a validated risk score such as the HEART (History, ECG, Age, Risk factors and Troponin) or TIMI (thrombolysis in myocardial infarction) score to risk stratify our patients into high‐, intermediate‐, and low‐risk strata. It was not feasible to calculate these scores with our available data. Instead, we chose to use a simple and practical risk‐stratification tool that we could feasibly derive from our data. Similar risk‐stratification techniques utilizing administrative data have been shown to be able to classify patients discharged from the ED into different strata of adverse outcomes.[11](#jah34511-bib-0011){ref-type="ref"}, [23](#jah34511-bib-0023){ref-type="ref"} In addition, we recognize that use of our risk‐stratification tool is likely to be less accurate when compared with validated tools.

Conclusions {#jah34511-sec-0027}
===========

Our population‐based study reported a lower observed rate of the composite outcome of cardiovascular death or MI associated with NIT following evaluation for chest pain in the ED. This lower event rate was driven by the high‐risk subgroup with no significant reductions noted in the intermediate‐ and low‐risk patient groups. These results suggest that NIT for CAD after ED discharge may currently be overutilized and that risk‐based testing should be considered for patients discharged from the ED for chest pain.
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